Clinically, low glutamine levels correlate with poor prognostic indicators—such as advanced age, tumor progression, hypoalbuminemia, elevated Carcinoembryonic Antigen (CEA), and C-reactive protein (CRP)—and predict shorter survival outcomes (9). This evidence concerns the gene CRP and neoplasm.